SMARCA4 缺陷性胸肉瘤治疗中纳武利尤单抗显著应答：病例报告
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report.
机构信息
The Department of Respiratory Medicine, Tokyo Medical & Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Cancer Center, Tokyo Medical & Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
出版信息
Immunotherapy. 2020 Jun;12(8):563-569. doi: 10.2217/imt-2019-0142. Epub 2020 May 3.
SMARCA4-deficient thoracic sarcoma is a rare tumor typically presenting as a mediastinal mass. The prognosis is estimated to be poor, and no effective treatment has been established. We present a case of a 76-year-old man who was diagnosed with SMARCA4-deficient thoracic sarcoma. The provisional diagnosis was carcinoma of unknown primary but subsequently corrected to SMARCA4-deficient thoracic sarcoma based on the panel-based cancer gene screening and immunohistochemistry. Cytotoxic chemotherapy as the first- and second-line did not reveal enough therapeutic effects but third-line therapy using nivolumab showed marked tumor regression, which was sustained. This is the first case report of SMARCA4-deficient thoracic sarcoma showing a good response to nivolumab. Immune checkpoint inhibitor might be therapeutic candidates for this type of tumor.
SMARCA4 缺陷性胸肉瘤是一种罕见的肿瘤，通常表现为纵隔肿块。据估计，预后较差，尚未确立有效的治疗方法。我们报告了一例 76 岁男性患者，被诊断为 SMARCA4 缺陷性胸肉瘤。最初的诊断为不明原发癌，但随后根据基于面板的癌症基因筛查和免疫组织化学检查，修正为 SMARCA4 缺陷性胸肉瘤。细胞毒性化疗作为一线和二线治疗没有显示出足够的治疗效果，但三线治疗使用纳武单抗显示出明显的肿瘤消退，并持续存在。这是首例报告显示纳武单抗对 SMARCA4 缺陷性胸肉瘤有良好反应的病例。免疫检查点抑制剂可能是这种类型肿瘤的治疗候选药物。
Zotero 插件